Distinct overlapping sequences at the carboxy-terminus of merlin regulate its tumour suppressor and morphogenic activity

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 9, 2012, Pages 2161-2175

  Laulajainen, Minja ^a   Melikova, Maria ^a   Muranen, Taru ^a   Carpén, Olli ^a,b   Grönholm, Mikaela ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Ezrin; Merlin; NF2

Indexed keywords

CYTOSKELETON PROTEIN; EZRIN; ISOPROTEIN; MERLIN;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CELL PROLIFERATION; CELL STRAIN COS1; CELL STRAIN HEK293; CERCOPITHECUS; CYTOSKELETON; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOBLOTTING; METABOLISM; MOLECULAR GENETICS; MOUSE; PHENOTYPE; PHOSPHORYLATION; PSEUDOPODIUM; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; ANIMALS; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; CYTOSKELETAL PROTEINS; CYTOSKELETON; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; MICE; MOLECULAR SEQUENCE DATA; NEUROFIBROMIN 2; PHENOTYPE; PHOSPHORYLATION; PROTEIN ISOFORMS; PSEUDOPODIA; TRANSFECTION;

EID: 84865416845     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01525.x     Document Type: Article

References (80)

1. Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992; 84: 603-18.
2. Kressel M, Schmucker B. Nucleocytoplasmic transfer of the NF2 tumour suppressor protein merlin is regulated by exon 2 and a CRM1-dependent nuclear export signal in exon 15. Hum Mol Genet. 2002; 11: 2269-78.
3. Muranen T, Grönholm M, Renkema GH, et al. Cell cycle-dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlin. Oncogene. 2005; 24: 1150-8.
4. Li W, You L, Cooper J, et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell. 2010; 140: 477-90.
5. Bianchi AB, Hara T, Ramesh V, et al. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet. 1994; 6: 185-92.
6. Chang LS, Akhmametyeva EM, Wu Y, et al. Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts. Genomics. 2002; 79: 63-76.
7. Sherman L, Xu HM, Geist RT, et al. Interdomain binding mediates tumour growth suppression by the NF2 gene product. Oncogene. 1997; 15: 2505-9.
8. Turunen O, Sainio M, Jääskeläinen J, et al. Structure-function relationships in the ezrin family and the effect of tumour-associated point mutations in neurofibromatosis 2 protein. Biochim Biophys Acta. 1998; 1387: 1-16.
9. Gary R, Bretscher A. Heterotypic and homotypic associations between ezrin and moesin, two putative membrane-cytoskeletal linking proteins. Proc Natl Acad Sci USA. 1993; 90: 10846-50.
10. Grönholm M, Sainio M, Zhao F, et al. Homotypic and heterotypic interaction of the neurofibromatosis 2 tumour suppressor protein merlin and the ERM protein ezrin. J Cell Sci. 1999; 112: 895-904.
11. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004; 10: 182-6.
12. Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med. 2004; 10: 175-81.
13. Heiska L, Melikova M, Zhao F, et al. Ezrin is key regulator of Src-induced malignant phenotype in three-dimensional environment. Oncogene. 2011; 30: 4953-62.
14. Gary R, Bretscher A. Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Mol Biol Cell. 1995; 6: 1061-75.
15. Huang L, Ichimaru E, Pestonjamasp K, et al. Merlin differs from moesin in binding to F-actin and in its intra- and intermolecular interactions. Biochem Biophys Res Commun. 1998; 248: 548-53.
16. Gonzalez-Agosti C, Wiederhold T, Herndon ME, et al. Interdomain interaction of merlin isoforms and its influence on intermolecular binding to NHE-RF. J Biol Chem. 1999; 274: 34438-42.
17. Gutmann DH, Haipek CA, Hoang Lu K. Neurofibromatosis 2 tumour suppressor protein, merlin, forms two functionally important intramolecular associations. J Neurosci Res. 1999; 58: 706-16.
18. Kissil JL, Johnson KC, Eckman MS, et al. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem. 2002; 277: 10394-9.
19. Xiao GH, Beeser A, Chernoff J, et al. p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem. 2002; 277: 883-6.
20. Alfthan K, Heiska L, Grönholm M, et al. Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization. J Biol Chem. 2004; 279: 18559-66.
21. Morrison H, Sherman LS, Legg J, et al. The NF2 tumour suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 2001; 15: 968-80.
22. Shaw RJ, Paez JG, Curto M, et al. The Nf2 tumour suppressor, merlin, functions in Rac-dependent signaling. Dev Cell. 2001; 1: 63-72.
23. Tang X, Jang SW, Wang X, et al. Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat Cell Biol. 2007; 9: 1199-207.
24. Laulajainen M, Muranen T, Carpén O, et al. Protein kinase A-mediated phosphorylation of the NF2 tumour suppressor protein merlin at serine 10 affects the actin cytoskeleton. Oncogene. 2008; 27: 3233-43.
25. Laulajainen M, Muranen T, Nyman TA, et al. Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumour suppressor merlin. Neoplasia. 2011; 13: 643-52.
26. Fernandez-Valle C, Tang Y, Ricard J, et al. Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet. 2002; 31: 354-62.
27. Hotulainen P, Lappalainen P. Stress fibers are generated by two distinct actin assembly mechanisms in motile cells. J Cell Biol. 2006; 173: 383-94.
28. Khosravi-Far R, White MA, Westwick JK, et al. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumourigenic transformation. Mol Cell Biol. 1996; 16: 3923-33.
29. Bashour AM, Meng JJ, Ip W, et al. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells. Mol Cell Biol. 2002; 22: 1150-7.
30. Giovannini M, Robanus-Maandag E, van der Valk M, et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 2000; 14: 1617-30.
31. Manent J, Oguievetskaia K, Bayer J, et al. Magnetic cell sorting for enriching Schwann cells from adult mouse peripheral nerves. J Neurosci Methods. 2003; 123: 167-73.
32. den Bakker MA, Riegman PH, Hekman RA, et al. The product of the NF2 tumour suppressor gene localizes near the plasma membrane and is highly expressed in muscle cells. Oncogene. 1995; 10: 757-63.
33. den Bakker MA, Tascilar M, Riegman PH, et al. Neurofibromatosis type 2 protein co-localizes with elements of the cytoskeleton. Am J Pathol. 1995; 147: 1339-49.
34. Böhling T, Turunen O, Jääskeläinen J, et al. Ezrin expression in stromal cells of capillary hemangioblastoma. An immunohistochemical survey of brain tumours. Am J Pathol. 1996; 148: 367-73.
35. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993; 363: 515-21.
36. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumour suppressor. Cell. 1993; 75: 826.
37. Jacoby LB, MacCollin M, Louis DN, et al. Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet. 1994; 3: 413-9.
38. Wallace AJ, Watson CJ, Oward E, et al. Mutation scanning of the NF2 gene: an improved service based on meta-PCR/sequencing, dosage analysis, and loss of heterozygosity analysis. Genet Test. 2004; 8: 368-80.
39. Golovnina K, Blinov A, Akhmametyeva EM, et al. Evolution and origin of merlin, the product of the Neurofibromatosis type 2 (NF2) tumour-suppressor gene. BMC Evol Biol. 2005; 5: 69.
40. Kazakov DV, Pitha J, Sima R, et al. Hybrid peripheral nerve sheath tumours: Schwannoma-perineurioma and neurofibroma-perineurioma. A report of three cases in extradigital locations. Ann Diagn Pathol. 2005; 9: 16-23.
41. Pearson MA, Reczek D, Bretscher A, et al. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell. 2000; 101: 259-70.
42. Gutmann DH, Geist RT, Xu H, et al. Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet. 1998; 7: 335-45.
43. Gautreau A, Manent J, Fievet B, et al. Mutant products of the NF2 tumour suppressor gene are degraded by the ubiquitin-proteasome pathway. J Biol Chem. 2002; 277: 31279-82.
44. Sainio M, Jääskeläinen J, Pihlaja H, et al. Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus. Neurology. 2000; 54: 1132-8.
45. Sainio M, Zhao F, Heiska L, et al. Neurofibromatosis 2 tumour suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J Cell Sci. 1997; 110: 2249-60.
46. Shaw RJ, McClatchey AI, Jacks T. Localization and functional domains of the neurofibromatosis type II tumour suppressor, merlin. Cell Growth Differ. 1998; 9: 287-96.
47. Gonzalez-Agosti C, Xu L, Pinney D, et al. The merlin tumour suppressor localizes preferentially in membrane ruffles. Oncogene. 1996; 13: 1239-47.
48. Lallemand D, Saint-Amaux AL, Giovannini M. Tumour-suppression functions of merlin are independent of its role as an organizer of the actin cytoskeleton in Schwann cells. J Cell Sci. 2009; 122: 4141-9.
49. Pelton PD, Sherman LS, Rizvi TA, et al. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene. 1998; 17: 2195-209.
50. Rosenbaum C, Kluwe L, Mautner VF, et al. Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients. Neurobiol Dis. 1998; 5: 55-64.
51. Flaiz C, Kaempchen K, Matthies C, et al. Actin-rich protrusions and nonlocalized GTPase activation in Merlin-deficient schwannomas. J Neuropathol Exp Neurol. 2007; 66: 608-16.
52. Gautreau A, Fievet BT, Brault E, et al. Isolation and characterization of an aggresome determinant in the NF2 tumour suppressor. J Biol Chem. 2003; 278: 6235-42.
53. Martin M, Roy C, Montcourrier P, et al. Three determinants in ezrin are responsible for cell extension activity. Mol Biol Cell. 1997; 8: 1543-57.
54. Xu HM, Gutmann DH. Merlin differentially associates with the microtubule and actin cytoskeleton. J Neurosci Res. 1998; 51: 403-15.
55. James MF, Manchanda N, Gonzalez-Agosti C, et al. The neurofibromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the filaments through a lateral association. Biochem J. 2001; 356: 377-86.
56. Turunen O, Wahlström T, Vaheri A. Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J Cell Biol. 1994; 126: 1445-53.
57. Shaw RJ, McClatchey AI, Jacks T. Regulation of the neurofibromatosis type 2 tumour suppressor protein, merlin, by adhesion and growth arrest stimuli. J Biol Chem. 1998; 273: 7757-64.
58. Tikoo A, Varga M, Ramesh V, et al. An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). J Biol Chem. 1994; 269: 23387-90.
59. Jung JR, Kim H, Jeun SS, et al. The Phosphorylation status of merlin is important for regulating the Ras-ERK pathway. Mol Cells. 2005; 20: 196-200.
60. Stokowski RP, Cox DR. Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations. Am J Hum Genet. 2000; 66: 873-91.
61. Obremski VJ, Hall AM, Fernandez-Valle C. Merlin, the neurofibromatosis type 2 gene product, and beta1 integrin associate in isolated and differentiating Schwann cells. J Neurobiol. 1998; 37: 487-501.
62. Yamauchi J, Miyamoto Y, Kusakawa S, et al. Neurofibromatosis 2 tumour suppressor, the gene induced by valproic acid, mediates neurite outgrowth through interaction with paxillin. Exp Cell Res. 2008; 314: 2279-88.
63. Somlyo AV, Bradshaw D, Ramos S, et al. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun. 2000; 269: 652-9.
64. Alblas J, Ulfman L, Hordijk P, et al. Activation of Rhoa and ROCK are essential for detachment of migrating leukocytes. Mol Biol Cell. 2001; 12: 2137-45.
65. Worthylake RA, Lemoine S, Watson JM, et al. RhoA is required for monocyte tail retraction during transendothelial migration. J Cell Biol. 2001; 154: 147-60.
66. Muranen T, Grönholm M, Lampin A, et al. The tumour suppressor merlin interacts with microtubules and modulates Schwann cell microtubule cytoskeleton. Hum Mol Genet. 2007; 16: 1742-51.
67. Hennigan RF, Foster LA, Chaiken MF, et al. Fluorescence resonance energy transfer analysis of merlin conformational changes. Mol Cell Biol. 2010; 30: 54-67.
68. Yogesha SD, Sharff AJ, Giovannini M, et al. Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumour suppressor. Protein Sci. 2011; 20: 2113-20.
69. Jacoby LB, MacCollin M, Barone R, et al. Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosomes Cancer. 1996; 17: 45-55.
70. Baser ME. Contributors to the International NF2 Mutation Database. The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat. 2006; 27: 297-306.
71. Ahronowitz I, Xin W, Kiely R, et al. Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum Mutat. 2007; 28: 1-12.
72. Ammoun S, Hanemann CO. Emerging therapeutic targets in schwannomas and other merlin-deficient tumours. Nat Rev Neurol. 2011; 7: 392-9.
73. Lallemand D, Manent J, Couvelard A, et al. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene. 2009; 28: 854-65.
74. Morrison H, Sperka T, Manent J, et al. Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res. 2007; 67: 520-7.
75. LaJeunesse DR, McCartney BM, Fehon RG. Structural analysis of Drosophila merlin reveals functional domains important for growth control and subcellular localization. J Cell Biol. 1998; 141: 1589-99.
76. Hung G, Faudoa R, Baser ME, et al. Neurofibromatosis 2 phenotypes and germ-line NF2 mutations determined by an RNA mismatch method and loss of heterozygosity analysis in NF2 schwannomas. Cancer Genet Cytogenet. 2000; 118: 167-8.
77. Bourn D, Evans G, Mason S, et al. Eleven novel mutations in the NF2 tumour suppressor gene. Hum Genet. 1995; 95: 572-4.
78. Kluwe L, Mautner VF. A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2. Hum Genet. 1996; 97: 224-7.
79. Gutmann DH, Hirbe AC, Haipek CA. Functional analysis of neurofibromatosis 2 (NF2) missense mutations. Hum Mol Genet. 2001; 10: 1519-29.
80. Yang C, Asthagiri AR, Iyer RR, et al. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function. Proc Natl Acad Sci USA. 2011; 108: 4980-5.